Halozyme says Enhanze effective on subcutaneous delivery of antibodies

By Elaine Rigoli

Tampa, Fla., June 2 - Halozyme Therapeutics, Inc. said studies evaluating the pharmacokinetics and tolerability of several subcutaneously injected antibody candidates with and without the company's Enhanze Technology (rHuPH20) platform in different animal models demonstrated significant increases in peak blood levels and a more rapid appearance in the bloodstream of antibody candidates injected subcutaneously with rHuPH20 compared to subcutaneous injections alone.

"The self-administration of antibodies by patients is evolving as the method of choice for chronic antibody therapies. A large number of monoclonal antibody therapies in development could potentially be converted from intravenous to subcutaneous administration with rHuPH20," vice president and chief scientific officer Gregory Frost said in a news release.

Halozyme's rHuPH20 is a highly purified, recombinant form of the naturally occurring human enzyme and is being investigated for its ability to break down hyaluronic acid, the space-filling "gel"-like substance that is a major component of tissues throughout the body.

Use of hyaluronidase may potentially change the route of administration or improve the bioavailability of new antibody therapies, the release said.

Halozyme is a Coronado, Calif.-based biopharmaceutical company developing recombinant human enzymes for the drug delivery, palliative care, oncology and infertility markets.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.